Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 5/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11987645 | 0.92 | NPC1 (0.45) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL7885441 | 0.87 | GABRA1 (0.44) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL11987006 | 0.85 | MAPT (0.58) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL10327011 | 0.84 | GRIN2B (0.37) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL13780070 | 0.80 | NPC1 (0.47) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL10327100 | 0.80 | NPC1 (0.37) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL10326651 | 0.77 | NPC1 (0.37) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL2757632 | 0.74 | HTR7 (0.35) | GABRA1GABRG2GABRB3GABRA3IDH1 | |
| SCHEMBL10326652 | 0.74 | IDH1 (0.35) | MAPTNPC1RAB9ASMN1; SMN2ATM | |
| SCHEMBL14198216 | 0.74 | IDH1 (0.40) | MAPTNPC1RAB9ASMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216698-B2 | Organic electroluminescence device, novel platinum complex compound and novel compound capable of being a ligand thereof | FUJIFILM CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8216698-B2 | Organic electroluminescence device, novel platinum complex compound and novel compound capable of being a ligand thereof | FUJIFILM CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20090261721-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE, NOVEL PLATINUM COMPLEX COMPOUND AND NOVEL COMPOUND CAPABLE OF BEING A LIGAND THEREOF | FUJIFILM CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090261721-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE, NOVEL PLATINUM COMPLEX COMPOUND AND NOVEL COMPOUND CAPABLE OF BEING A LIGAND THEREOF | FUJIFILM CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090261721-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE, NOVEL PLATINUM COMPLEX COMPOUND AND NOVEL COMPOUND CAPABLE OF BEING A LIGAND THEREOF | L1CAM, PDCD1LG2, CD274 | MAPT 2945/4885NPC1 4278/4885RAB9A 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.